A comparison of the 2022 USPSTF and 2019 ACC/AHA guidelines for daily aspirin use for primary prevention, by age
| Age 40 to 60 | Age 60 to 70 | Age > 70 | |
|---|---|---|---|
| USPSTF 20221 | Individualize for risk > 10% for CVD events using pooled cohort equation (grade C) | No aspirin (grade D) | No aspirin (grade D) |
| ACC/AHA 201910 | Individualize for higher risk patients (COR IIb/LOE A) | Individualize for higher risk patients (COR IIb/LOE A) | No aspirin (COR III/LOE B-R) |
ACC = American College of Cardiology; AHA = American Heart Association; COR = class of recommendation; COR IIb/LOE A = high-quality evidence showing treatment may be reasonable, but effectiveness is not well established; COR III/LOE B-R = moderate-quality evidence showed no benefit and potential harm; CVD = cardiovascular disease; grade C = small benefit in select patients; grade D = no net benefit or harm outweighs benefit; LOE = level of evidence